Vanguard Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
Other funds holding MLTX
Vanguard Asset Management's MLTX Position: Q3 2026 in Review
Vanguard Asset Management held its MoonLake Immunotherapeutics (MLTX) position steady in Q3 2026 at 36,195 shares worth $423K. The position accounts for ﹤0.01% of the portfolio, ranked #2240.
Vanguard Asset Management first reported a position in MLTX in Q1 2026 and has held it in 3 quarters since. The position peaked at $705K in Q2 2026. 168 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.
- Vanguard Asset Management held 36,195 shares of MoonLake Immunotherapeutics worth $423K as of Q3 2026.
- Vanguard Asset Management left its MoonLake Immunotherapeutics share count unchanged in Q3 2026.
- MoonLake Immunotherapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #2240 holding.
- Vanguard Asset Management first reported a position in MoonLake Immunotherapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Asset Management's MoonLake Immunotherapeutics position peaked at $705K in Q2 2026.
- 168 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.
Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.